Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$4.08M+460.79%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jennifer Lynne Bath
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 76
- Beta
- 0.83
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -5.13
Financials
Revenue
$4.08M+460.8%Net Income
$-3.83M-2672.5%EBITDA
$-4.06M-2310.4%Free Cash Flow
$-2.52MEPS (diluted)
$-0.08-210.2%Shares Outstanding (diluted)
46.71M+2236.7%Operating Expenses
$6.76MCash & Debt
$11.33MReturn of Capital
$0.00Revenue by Segment (annual)
$15.41MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $15.32M | $-13.74M | $-0.30 |
| 2025 | $24.52M | $-30.23M | $-0.90 |
| 2024 | $24.52M | $-26.11M | $-1.03 |
| 2023 | $20.66M | $-26.56M | $-1.07 |
| 2022 | $19.36M | $-16.71M | $-0.87 |
| 2021 | $17.91M | $-7.34M | $-0.45 |
| 2020 | $14.72M | $-5.18M | $-0.36 |
| 2019 | $10.93M | $-7.62M | $-0.61 |
| 2018 | $5.44M | $-5.17M | $-0.57 |
| 2017 | $2.63M | $-5.38M | $-1.36 |
| 2016 | $1.90M | $151.0K | $0.10 |
| 2015 | $0.00 | $-62.5K | $-0.11 |
| 2014 | $0.00 | $68.0K | $0.11 |
| 2013 | $0.00 | $-95.6K | $-0.18 |
Valuation
HYFThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (3)
- Newszacks.com·4h ago·Negative
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.07 per share a year ago.
View source ↗ - Newsmarketbeat.com·5h ago·Negative
MindWalk Q1 Earnings Call Highlights MindWalk NASDAQ: HYFT reported first-quarter fiscal 2027 revenue of CAD 3.8 million, up 21% from CAD 3.2 million a year earlier, as the company continued investing in commercialization of its ReefIQ biological-data platform and expanded its drug discovery partnership model.
View source ↗ - Newsbusinesswire.com·7h ago·Neutral
MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027 AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today reported financial results for its fiscal 2027 first quarter ended July 31, 2026. The quarter marked the commercial launch of ReefIQ™, MindWalk's data platform, and the start of its shift toward recurring, platform-based revenue. Revenue increased 21.3% year over year to…
View source ↗
Earnings
Mon, Sep 14(date passed)
Consensus estimate $-0.05 per share
Typical surprise -50.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 22$-0.06 vs $-0.05miss
- Thu, Mar 12$-0.06 vs $-0.04miss
- Mon, Dec 15$-0.05 vs $-0.01miss
- Mon, Sep 15$-0.07 vs $-0.04miss
- Tue, Jul 29$-0.04 vs $-0.02miss
- Fri, Mar 28$-0.06 vs $-0.06beat
Estimates and results for HYFT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HYFT officers and directors.
No open-market trades in the recent filings. All 22 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
22 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HYFT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.